PROCTER AND GAMBLE
SpecialtyPROCTER AND GAMBLE is a specialty pharmaceutical company focused on Infectious Disease, Neurology, Dermatology.
PROCTER AND GAMBLE at a Glance
- Strong track record with 89% execution quality across 21 trials
- Fast trial execution (3 months median completion)
PROCTER AND GAMBLE's Key Drugs
PROCTER AND GAMBLE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PROCTER AND GAMBLE's Recent FDA Approvals
New NDA/BLA approvals for PROCTER AND GAMBLE over the last two years — novel drugs only, excluding generics and label supplements.
PROCTER AND GAMBLE's Therapeutic Areas
PROCTER AND GAMBLE's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PROCTER AND GAMBLE's Top Competitors
PROCTER AND GAMBLE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PROCTER AND GAMBLE Pipeline Snapshot
PROCTER AND GAMBLE has 4 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 1 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/4 completed
- • Speed: 3 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1953-02-06
- Latest
- 1998-02-17
- Applications
- 3
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges